| Ytd | -64.89% | |
| 1y | -83.66% |
| Open | 2.45 | Prev Close | 2.51 | Low | 2.42 | High | 2.70 | Mkt Cap | 1.69M |
| Vol | 24.61K | Avg Vol | 66.33K | EPS | 28.07 | P/E | 0.09 | Forward P/E | N/A |
| Beta | 2.46 | Short Ratio | 0.09 | Inst. Own | 2.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.62 | 200-d Avg | 6.20 | 1yr Est | 700.00 |
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDTJERUSALEM, Aug. 24, 2026 /PRNewswire
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswir
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or t
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the compan
Scinai Immunotherapeutics shares are surging Friday after it announced fresh financing tied to a pri
US stocks mixed, Nasdaq up 100pts. Dow down 0.35%, Nasdaq up 0.56%, S&P 500 up 0.19%. Tech up 1.
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company") a biophar
Financing led by institutional life sciences investor, with participation from new and existing inve
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai"
Scinai Immunotherapeutics (NASDAQ:SCNI) reported quarterly losses of $(3.56) per share. The company
JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" o
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharma
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today anno
JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai"
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the recipient of a
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI);("Scinai" or the "Company"), today anno
JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" o
JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or
JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", o
JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the target of a la
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report)'s share price shot up
JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or
Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' s